alogliptin + sulfonylurea

Alogliptin + sulfonylurea is an oral combination therapy for type 2 diabetes mellitus, wherein alogliptin, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, is administered together with a sulfonylurea such as glimepiride or glyburide. Alogliptin increases incretin hormone levels, leading to glucose-dependent insulin secretion and reduced glucagon production, while sulfonylureas stimulate pancreatic beta cells to release insulin independent of blood glucose levels. This combination is used in patients with inadequate glycemic control on sulfonylurea monotherapy, typically as an adjunct to diet and exercise. The combination improves glycemic control but increases the risk of hypoglycemia relative to either agent alone.